Articles from ADMA Biologics, Inc.

FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 5, 2025, at 11:35 a.m. ET.

Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET

FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA’s presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT.

Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital

3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y

Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market.

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York, NY on September 17, 2024, at 3:05 p.m. ET.

Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties

2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y

Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET

1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y

Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET

FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life

RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET.

Executive Search Initiated for CFO Replacement

4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million

Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million

New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt

Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval

FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency

3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase

Conference Call Scheduled for November 8, 2023, at 4:30 p.m. ET

2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase

Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ET

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth

1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase

Conference Call Scheduled for May 10, 2023, at 4:30 p.m. ET

Reduces Nominal Interest Rate by 1%

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase

Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 3,146,853 shares of common stock. The gross proceeds from the exercise of the overallotment option were $9 million, bringing the total gross proceeds to ADMA from the offering to $69 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  

Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million

3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth